Plus Therapeutics Net Income From Continuing Ops Over Time
| PSTV Stock | USD 0.26 0.03 13.04% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Plus Therapeutics Performance and Plus Therapeutics Correlation. What growth prospects exist in Biotechnology sector? Can Plus capture new markets? Factors like these will boost the valuation of Plus Therapeutics. Anticipated expansion of Plus directly elevates investor willingness to pay premium valuations. Valuation analysis balances hard financial data with qualitative growth assessments. While each Plus Therapeutics valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Earnings Share (0.96) | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets | Return On Equity |
The market value of Plus Therapeutics is measured differently than its book value, which is the value of Plus that is recorded on the company's balance sheet. Investors also form their own opinion of Plus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Plus Therapeutics' true underlying value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Because Plus Therapeutics' market value can be influenced by many factors that don't directly affect Plus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Plus Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Plus Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Plus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Plus Therapeutics and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (3 M) | (18.6 M) | (14 M) | (23.8 M) | (25 M) | (22.5 M) | (21.4 M) |
| BLRX | (17 M) | (17 M) | (17 M) | (17 M) | (11.1 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
| THAR | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (2.4 M) | (2.2 M) | (8.5 M) | (9.3 M) | (12.2 M) | (11 M) | (10.4 M) |
| AIMD | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (10 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| LPCN | 76.7 K | 76.7 K | 76.7 K | (10.6 M) | (20.4 M) | (18.2 M) | (19 M) | (21 M) | (11.7 M) | (13 M) | (21 M) | (634.4 K) | (10.8 M) | (16.3 M) | 8.4 K | 9.6 K | 10.1 K |
Plus Therapeutics and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Plus Therapeutics | PSTV |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2710 Reed Road, |
| Exchange | NASDAQ Exchange |
USD 0.26
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.